Townsend Kirk P, Shytle Doug R, Bai Yun, San Nan, Zeng Jin, Freeman Melissa, Mori Takashi, Fernandez Francisco, Morgan David, Sanberg Paul, Tan Jun
Neuroimmunology Laboratory, Department of Psychiatry and Behavioral Medicine, University of South Florida College of Medicine, Tampa, Florida 33613, USA.
J Neurosci Res. 2004 Oct 15;78(2):167-76. doi: 10.1002/jnr.20234.
Recent studies have shown that the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) possess antiinflammatory and immunomodulatory properties, distinct from their action of lowering serum lipid levels. Moreover, results of epidemiological studies suggest that long-term use of statins is associated with a decreased risk for Alzheimer's disease (AD). Interestingly, lovastatin (one of the most commonly used anticholesterol drugs) treatment of vascular-derived cells has been reported to antagonize activation of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway, and it is well known that the JAK/STAT pathway plays a central role in interferon-gamma (IFN-gamma)-induced microglial CD40 expression. We and others have previously reported that microglial CD40 expression is significantly induced by IFN-gamma and amyloid-beta (Abeta) peptide. Moreover, it has been shown that CD40 signaling is critically involved in microglia-related immune responses in the CNS. In this study, we examined the putative role of lovastatin in modulation of CD40 expression and its signaling in cultured microglia. RT-PCR, Western immunoblotting, and flow cytometry data show that lovastatin suppresses IFN-gamma-induced CD40 expression. Additionally, lovastatin markedly inhibits IFN-gamma-induced phosphorylation of JAK/STAT1. Furthermore, lovastatin is able to suppress microglial tumor necrosis factor-alpha, interleukin (IL)-beta1 and IL-6 production promoted either by IFN-gamma or by Abeta peptide challenge in the presence of CD40 cross-linking. To characterize further lovastatin's effect on microglial function, we examined microglial phagocytic capability following CD40 cross-linking. Data reveal that lovastatin markedly attenuates CD40-mediated inhibition of microglial phagocytosis of Abeta. These results provide an insight into the mechanism of the beneficial effects of lovastatin in neurodegenerative disorders, particularly Alzheimer's disease.
最近的研究表明,3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂(他汀类药物)具有抗炎和免疫调节特性,这与其降低血清脂质水平的作用不同。此外,流行病学研究结果表明,长期使用他汀类药物与阿尔茨海默病(AD)风险降低有关。有趣的是,据报道,洛伐他汀(最常用的抗胆固醇药物之一)对血管衍生细胞的治疗可拮抗Janus激酶(JAK)/信号转导和转录激活因子(STAT)信号通路的激活,并且众所周知,JAK/STAT通路在干扰素-γ(IFN-γ)诱导的小胶质细胞CD40表达中起核心作用。我们和其他人之前曾报道,IFN-γ和淀粉样β(Aβ)肽可显著诱导小胶质细胞CD40表达。此外,已经表明CD40信号传导在中枢神经系统中与小胶质细胞相关的免疫反应中起关键作用。在本研究中,我们研究了洛伐他汀在调节培养的小胶质细胞中CD40表达及其信号传导方面的假定作用。逆转录-聚合酶链反应(RT-PCR)、蛋白质免疫印迹和流式细胞术数据表明,洛伐他汀可抑制IFN-γ诱导的CD40表达。此外,洛伐他汀显著抑制IFN-γ诱导的JAK/STAT1磷酸化。此外,在存在CD40交联的情况下,洛伐他汀能够抑制IFN-γ或Aβ肽刺激所促进的小胶质细胞瘤坏死因子-α、白细胞介素(IL)-β1和IL-6的产生。为了进一步表征洛伐他汀对小胶质细胞功能的影响,我们检测了CD40交联后小胶质细胞的吞噬能力。数据显示,洛伐他汀显著减弱了CD40介导的对小胶质细胞吞噬Aβ的抑制作用。这些结果为洛伐他汀在神经退行性疾病,特别是阿尔茨海默病中的有益作用机制提供了见解。